Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 247 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma Patients Clear all
Completed Not applicable Interventional Results available

SENSIMED Triggerfish Safety and Tolerability

NCT01319617
View directory record Official record
Conditions
Glaucoma
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 6, 2026, 11:51 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine Tartrate Ophthalmic 0.025%
Drug
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 4 Interventional

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

NCT00300079
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 6, 2026, 11:51 AM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG) Patient
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 6, 2026, 11:51 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Observational Study of How Patients Take Eye Drops

NCT00750646
View directory record Official record
Conditions
Glaucoma
Interventions
MEMS cap
Device
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01215786
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 6, 2026, 11:51 AM EDT
Completed No phase listed Observational

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Survey
Other
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

NCT00051181
View directory record Official record
Conditions
Glaucoma, Angle-Closure, Ocular Hypertension
Interventions
Travoprost (0.004%), Latanoprost (0.005%)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

NCT00047528
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 6, 2026, 11:51 AM EDT
Terminated Phase 1 Interventional

Safety Study of Latanoprost Slow Release Insert

NCT01180062
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Latanoprost, Arm 2, Latanoprost SR insert
Drug
Lead sponsor
Daniel Moore
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Sep 6, 2026, 11:51 AM EDT
Not listed Not applicable Interventional

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

NCT05280366
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Streamline Surgical System, iStent Inject W
Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
18
States / cities
Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 6, 2026, 11:51 AM EDT
Not listed Phase 2 Interventional

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

NCT02174991
View directory record Official record
Conditions
Glaucoma
Interventions
Rho-Kinase Inhibitor (AR-12286)
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 2 Interventional

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

NCT00317577
View directory record Official record
Conditions
Glaucoma, Open Angle
Interventions
brimonidine, timolol
Drug
Lead sponsor
Chicago Center for Vision Research
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
12
States / cities
Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2006 · Synced Sep 6, 2026, 11:51 AM EDT
Withdrawn No phase listed Observational

Prevalence of Dyschromatopsia in Glaucoma Patients

NCT01994564
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 4 Interventional Results available

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

NCT00440011
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03% eye drops, travoprost 0.004% eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 6, 2026, 11:51 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Outcomes in Cataract Surgery With OMNI Canaloplasty vs Cataract Surgery With OMNI Canaloplasty and Hydrus Stent

NCT05949242
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI canaloplasty, Hydrus microstent
Device
Lead sponsor
Ridge Eye Care
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
4
States / cities
Marysville, California • Oroville, California • Paradise, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Not applicable Interventional Results available

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

NCT02700984
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG)
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT02207621
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Not applicable Interventional Results available

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

NCT01539239
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Hydrus Aqueous Implant, Cataract surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 6, 2026, 11:51 AM EDT
Recruiting No phase listed Observational

DSLT for Reducing Medication in Glaucoma

NCT07390890
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Voyager DSLT
Device
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2009 · Synced Sep 6, 2026, 11:51 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

NCT02102750
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Preservative free tafluprost opthalmic solution
Drug
Lead sponsor
Santen Oy
Industry
Eligibility
1 Month to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Sep 6, 2026, 11:51 AM EDT